Leap Investments’s Niagen Bioscience NAGE Stock Holding History

Leap Investments’s Portfolio NAGE Stock Details NAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-16,100	Closed	-$69K	–	592
2019 Q4	$69K	Buy	+16,100	New	+$57.2K	0.03%	390

Other funds holding NAGE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return

TCM

Tieton Capital Management Yakima, Washington $299M AUM 54.55% 1-Year Est. Return

UIC

Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Sycale Advisors New York $201M AUM 2.35% 1-Year Est. Return

JMPWA

JP Morgan Private Wealth Advisors San Francisco, California $35B AUM 24.26% 1-Year Est. Return

Leap Investments's NAGE Position: Q1 2020 in Review

Leap Investments sold out of Niagen Bioscience (NAGE) in Q1 2020, closing a stake of 16,100 shares — an estimated $69K sold.

Leap Investments first reported a position in NAGE in Q4 2019 and held it in 1 quarter. The position peaked at $69K in Q4 2019. 61 funds tracked by Wall St. Rank hold NAGE as of Q1 2020.

Leap Investments reported no remaining Niagen Bioscience position as of Q1 2020 after selling out during the quarter.
Leap Investments sold 16,100 Niagen Bioscience shares in Q1 2020, an estimated $69K.
Leap Investments first reported a position in Niagen Bioscience in Q4 2019 and held it in 1 quarter.
Leap Investments's Niagen Bioscience position peaked at $69K in Q4 2019.
61 funds tracked by Wall St. Rank held Niagen Bioscience as of Q1 2020.

Based on Leap Investments's 13F filing for Q1 2020, filed 15 May 2020.